


## AUA VIRTUAL EXPERIENCE



## Value-Based Health Care (VBHC) decisions in Localized Prostate Cancer Treatments: A single institution experience

Pedro Isaacsson Velho<sup>1</sup>, Maiara Floriani<sup>1</sup>, Maria Cristina Matte<sup>1</sup>, Marina Bessel<sup>1</sup>, Renata Adamy<sup>1</sup>, Mohamed Parrini<sup>1</sup>, Luiz Antonio Nasi<sup>1</sup>, Mateus Weber de Bacco<sup>1</sup>, Mauro Weiss<sup>1</sup>, Eduardo Carvalhal<sup>1</sup>, Gisele Nader Bastos<sup>1</sup>.

<sup>1</sup> Hospital Moinhos de Vento, Porto Alegre, Brazil



## AUA VIRTUAL EXPERIENCE

 Despite comparable outcomes of the different treatment options of localized prostate cancer (LPC), the side effects, the impact on quality of life (QoL) and the cost are diverse.

• In the era of shared decision-making, where health organizations make value-based health care (VBHC) decisions, the improvement of instruments to evaluate the different treatment options is crucial.

• The Expanded Prostate Cancer Index Composite (EPIC-26), a validated questionnaire that measures health-related QoL was applied to all patients at baseline and at 6 months, regardless of the treatment received in a single institution.



## AUA VIRTUAL EXPERIENCE

Table 1: EPIC-26 Global Score for patients at baseline and at 6 months.

|                                | EPIC26 Global Score Average [95 Cl] |                       |         |
|--------------------------------|-------------------------------------|-----------------------|---------|
| Domain Summary Scores          | Baseline                            | 6-month               | P value |
| Urinary Incontinence           | 96.26 (94.23 – 98.29)               | 85.90 (80.04 – 91.77) | 0.001   |
| Urinary Irritative/Obstructive | 88.53 (85.56 – 91.51)               | 88.81 (84.22 – 93.41) | 0.92    |
| Bowel                          | 95.42 (93.41 – 97.42)               | 94.77 (91.04 – 98.45) | 0.73    |
| Sexual                         | 66.99 (61.02 – 72.96)               | 41.28 (32.70 – 49.86) | <0.001  |
| Hormonal                       | 90.80 (88.24 – 93.36)               | 91.38 (87.34 – 95.41) | 0.81    |

**Conclusion:** After treatment, the EPIC-26 was capable to identify worsening QoL in *Urinary Incontinence* and *Sexual* domains in patients who received treatment for LPC. Patient Reported Outcomes instruments may be used to help **institutions** and **patients** to improve VBHC decisions.